Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin, MD, Moshe Y. Levy, MD, Andrew P. Dalovisio, MD, Nizar J. Bahlis, MD, Melhem Solh, MD, Michael Sebag, MD PhD FRCPC, Andrzej Jakubowiak, MD PhD, Yogesh S. Jethava, MBBS, MD FRCPath, MRCP, Caitlin L. Costello, MD, Michael P. Chu, MD, Michael R. Savona, MD, Cristina Gasparetto, MD, Suzanne Trudel, MD MSC, FRCPC, Jeffrey Chou, MD PhD, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Heike I. Krupka, PhD PMP, Noopur S. Raje, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133355

Published: 2020

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

Hannah Cherniawsky, BSc,MD, Zack M. Breckenridge, BSc, Irwindeep Sandhu, MD FRCPC, Michael P. Chu, MD, Joanne D. Hewitt, NP, PhD, Ismail Ismail, Andrew R Belch, MD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2018-99-117705

Published: 2018

Journal Articles

Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma

Michael P. Chu, MD, Eva Baigorri, Jitra Kriangkum, PhD, Joanne D. Hewitt, NP, PhD, Andrew Belch, Christopher P. Venner, Irwindeep Sandhu, MDFRCPC, Linda M. Pilarski, PhD

Blood (2017) 130 (Supplement 1): 1928.

https://doi.org/10.1182/blood.V130.Suppl_1.1928.1928

Published: 2017

Journal Articles

The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data

Hannah Cherniawsky, BSc, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Joanne D. Hewitt, NP, PhD, Ismail Ismail, Andrew Belch, Linda M. Pilarski, PhD, Tatiana Nikitina, PhD, Christopher P. Venner, MD

Blood (2017) 130 (Supplement 1): 3132.

https://doi.org/10.1182/blood.V130.Suppl_1.3132.3132

Published: 2017

Journal Articles

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Zack M. Breckenridge, BSc, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Ismail Ismail, Jason Tay, MD FRCPC, Peter Duggan, MD FRCPC, Andrew Belch, Joanne D. Hewitt, NP, PhD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner

Blood (2017) 130 (Supplement 1): 1859.

https://doi.org/10.1182/blood.V130.Suppl_1.1859.1859

Published: 2017

Journal Articles

Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy

Michael P. Chu, MD, Christopher P. Venner, MD, Irwindeep Sandhu, MD, Eva Baigorri, PhD, Jitra Kriangkum, PhD, Joanne D Hewitt, RN, BSN, NP, Andrew Belch, Linda M. Pilarski, PhD

Blood (2016) 128 (22): 2113.

https://doi.org/10.1182/blood.V128.22.2113.2113

Published: 2016

Journal Articles

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Michael P. Chu, MD, Andrew Belch, MD, Lixia Pei, PhD, Xue (Loya) Yang, PhD, Tadeusz Robak, MD PhD, Brendan Rooney, PhD, Andrew Cakana, MD, Helgi van de Velde, MD PhD, Michael B Sawyer, MD

Blood (2015) 126 (23): 1477.

https://doi.org/10.1182/blood.V126.23.1477.1477

Published: 2015

Journal Articles

Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis

Blood (2015) 126 (23): 1536.

https://doi.org/10.1182/blood.V126.23.1536.1536

Published: 2015

Journal Articles

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Debra K Czerwinski, Steven R Long, MD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Michael P. Chu, MD, Ami Okada, PhD, Kathleen A McDonald, BA, Holbrook E Kohrt, MD PhD, Nancy L Bartlett, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD MMSc, Leo I. Gordon, MD, Robert Coffman, PhD, Robert Janssen, MD, Ronald Levy, MD

Blood (2015) 126 (23): 1539.

https://doi.org/10.1182/blood.V126.23.1539.1539

Published: 2015

Journal Articles

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 5078.

https://doi.org/10.1182/blood.V122.21.5078.5078

Published: 2013

Journal Articles

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Michael P Chu, MD, Jessica Lieffers, Andrew R Belch, MD, Neil Chua, MD, FRCPC, Amelie Fontaine, MD, Randeep Sangha, A. Robert Turner, MD, FRCPC, Sunita Ghosh, PhD, Michael Sawyer, MD

Blood (2013) 122 (21): 3023.

https://doi.org/10.1182/blood.V122.21.3023.3023

Published: 2013

NARROW

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse

Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma

The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Ex Vivo Modeling of Multiple Myeloma Provides Basis for Studying Treatment Combinations and Immunotherapy

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Indolent Non-Hodgkin Lymphoma: Skeletal Muscle Density Predicts Overall Survival With Rituximab Based Chemotherapy

Aggressive Non-Hodgkin Lymphoma: Predictive Value Of Sarcopenia and Skeletal Muscle Density On Prognosis With Rituximab Containing Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only